Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immunocore Named One of Fierce 15 Leading Biotechs of 2013

Published: Thursday, September 26, 2013
Last Updated: Wednesday, September 25, 2013
Bookmark and Share
Immunocore ranked among the top private biotech firms globally.

Immunocore Limited has been named by FierceBiotech as one of 2013’s Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is Fierce Biotech’s eleventh annual Fierce 15 selection.

“Immunocore offers an interesting early-stage approach to rallying the immune system against cancer,” said FierceBiotech Executive Editor Ryan McBride. “Its T-cell receptor technology has taken many years to invent from scratch, and the hard work has begun to pay dividends with two recent pharma partnership deals.”

The company’s world-leading platform of bi-specific biological drugs, called ImmTACs (Immune mobilizing mTCR Against Cancer), exploit the power of T Cell Receptors (TCRs) to recognize intracellular changes that occur during cancer or viral infection.

This unique recognition ability of TCRs sets them apart from traditional antibody-based therapies that can only recognize changes on the surface of cells, and provides, for the first time, the ability to develop extremely potent targeted therapies for cancers that are poorly served.

A particular feature is that the ImmTACs can be directed to target and destroy only the cancerous cells, avoiding damage to healthy cells.

The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is in Phase I/II clinical trials in the UK and USA.

This summer, Immunocore announced two major partnership agreements with Genentech, a member of Roche Group, and GlaxoSmithKline to discover, develop and commercialize ImmTAC therapies against multiple targets.

James Noble, Chief Executive Officer of Immunocore, commented: “We are delighted to receive this prestigious award from FierceBiotech and be ranked among the top private biotech firms globally. This award recognizes 14 years of work to develop our technology and create a robust and reproducible platform, which has been validated through our two significant partnership deals, enabling our ImmTACs to be deployed as the basis of breakthrough treatments for cancers where there is a large unmet medical need.”

The Fierce 15 celebrates the spirit of being “fierce” - championing innovation and creativity, even in the face of intense competition.

An internationally recognized daily newsletter reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories.

Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

A complete list of “Fierce 15” companies - the online newsletter’s eleventh annual selection - is available at www.fiercebiotech.com.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immunocore and MedImmune Win the SCRIP Award
Immunocore and MedImmune are working together to generate ImmTACs against selected cancer targets.
Thursday, December 11, 2014
Immunocore and Lilly Enter Immunotherapy Agreement
Agreement to co-discover and co-develop novel cancer therapies.
Thursday, July 17, 2014
Immunocore Announces Re-organization of its Executive Management to Support Business Growth
Re-organization to support the continuing growth of Immunocore and Adaptimmune.
Thursday, March 27, 2014
Immunocore and MedImmune Enter Immunotherapy Agreement
Companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
Wednesday, January 08, 2014
Immunocore Appoints New Chairman of the Board
Dr Jonathan Knowles appointed as Company’s new executive Chairman of the Board of Directors.
Monday, November 18, 2013
Immunocore Appoints Chairman
Immunocore Limited announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect.
Thursday, November 14, 2013
Immunocore Achieves Research Milestone in GSK Collaboration
Under the agreement announced in July, Immunocore will receive up to £142 million in pre-clinical milestone payments across the targets.
Thursday, November 07, 2013
Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma
IMCgp100 for has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed.
Monday, November 04, 2013
Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma
Phase IIa study to optimize the dosing regimen and maximize the efficacy of IMCgp100.
Thursday, October 31, 2013
Immunocore and Genentech Enter Strategic Alliance
Licensing agreement to develop ImmTACs for multiple cancer targets.
Thursday, June 27, 2013
Revolutionary New Cancer Targeting Technology Described in Nature Medicine
Immunocore scientists manage to overcome cancer problem by boosting the ability of cancer-specific TCRs.
Monday, May 07, 2012
Scientific News
New CAR T Cell Therapy Using Double Target Aimed at Solid Tumors
Researchers at Penn University have described how antibody, carbohydrate combination could apply to range of cancer types.
New Nanoparticle Technology Developed to Treat Aggressive Thyroid Cancer
Researchers from Brigham and Women’s Hospital have developed a nanoplatform that can deliver RNAi agents to sites of anaplastic thyroid cancer.
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!